Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CS32582 in Healthy Adults
NCT06224595Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CS32582 in psoriasis (11 arms), sponsored by Akeso, Inc. Primary endpoints: Incidence and Severity of Adverse Events (AEs), Area Under the Curve and 3 more. Started Mar 2024; status: completed.
02
Drugs
CS32582
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06224595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224595.